Skip to content
Screener

ImmunityBio, Inc. IBRX Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Gilead Sciences logo
Gilead SciencesGILD
$3.18B-38.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$84.79M+122%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemMarch 31, 2026December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents$205,194$88,334
Marketable securities175,685154,484
Accounts receivable, net43,27142,571
Inventories547910
Due from related parties346
Prepaid expenses and other current assets26,18227,761

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s cash & equivalents?
ImmunityBio, Inc. (IBRX) reported cash & equivalents of $205.19M in Q1 2026.
How has ImmunityBio, Inc.'s cash & equivalents changed year-over-year?
ImmunityBio, Inc.'s cash & equivalents increased by 238.3% year-over-year, from $60.66M to $205.19M.
What is the long-term trend for ImmunityBio, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cash & equivalents has grown at a 20.4% compound annual growth rate (CAGR), from $34.92M to $88.33M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about ImmunityBio, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude